Purdue asserts that Collegium infringes U.S. Patent No. 9,693,961, which covers improved oxycodone hydrochloride compositions, both by filing an NDA and by making and selling the now-approved Xtampza 00ae ER oxycodone extended release capsules. This marks the latest in a series of lawsuits filed by Purdue alleging Xtampza 00ae infringes Purdue patents.
By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
SHARE THIS POST
